AcroViz Inc.
【AEA 2019 Alumni】
AcroViz develops novel imaging biomarkers for brain health, in an effort to prolong human health span and aims to end dementia with state-ofart technologies. Comprising of members who were research fellows at eminent academia and experienced industrial professionals, our team are devoted to advance scientific research, its clinical significance and application, as well as commercialization of our technologies to achieve extended impact. Our first product: AcroViz Axonal Brain Age – Brain Health Report, is the first to the market, adopting diffusion Magnetic Resonance Imaging (MRI) and Machine Learning techniques to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk and prognosis of dementia, such as Alzheimer’s Disease (AD). AcroViz aims to end dementia with advanced neuroimaging technologies, currently working with medical or health-care institutions, and pharma or medical device companies, on various clinical trials to validate the effectiveness of intervention on MCI patients.
Nominated by
Center for Industry Collaboration and Innovation Incubation, National Chengchi University
The founding team, a group of academic scientists, based on their publication in the “Science” journal, developed the “Axonal Brain Age”. It is the first product adopting diffusion Magnetic Resonance Imaging and Machine Learning techniques, to provide accurate and objective brain health assessment, which can serve as a Mild Cognitive Impairment (MCI) marker in predicting the risk of Alzheimer’s Disease conversion. As global ageing phenomenon aggravates, dementia has caused huge medical costs and society costs, and has no better solution up to now, AcroViz aims to end dementia with advanced neuroimaging technologies. AcroViz’s vision is for human being to benefit from “better brain health and longer health span”.